BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 28318145)

  • 1. A multicenter study on PIVKA reference interval of healthy population and establishment of PIVKA cutoff value for hepatocellular carcinoma diagnosis in China.
    Qin X; Tang G; Gao R; Guo Z; Liu Z; Yu S; Chen M; Tao Z; Li S; Liu M; Wang L; Hou L; Xia L; Cheng X; Han J; Qiu L
    Int J Lab Hematol; 2017 Aug; 39(4):392-401. PubMed ID: 28318145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA.
    Wu J; Xiang Z; Bai L; He L; Tan L; Hu M; Ren Y
    Cancer Biomark; 2018; 23(2):235-242. PubMed ID: 30103302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical application of PIVKA-II in hepatocellular carcinoma and chronic liver diseases: A multi-center study in China.
    Ji J; Liu L; Jiang F; Wen X; Zhang Y; Li S; Lou J; Wang Y; Liu N; Guo Q; Jia Y; Gao C
    J Clin Lab Anal; 2021 Nov; 35(11):e24013. PubMed ID: 34590755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein induced by vitamin K absence or antagonist-II (PIVKA-II) specifically increased in Italian hepatocellular carcinoma patients.
    Viggiani V; Palombi S; Gennarini G; D'Ettorre G; De Vito C; Angeloni A; Frati L; Anastasi E
    Scand J Gastroenterol; 2016 Oct; 51(10):1257-62. PubMed ID: 27227515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients.
    Lim TS; Kim DY; Han KH; Kim HS; Shin SH; Jung KS; Kim BK; Kim SU; Park JY; Ahn SH
    Scand J Gastroenterol; 2016 Mar; 51(3):344-53. PubMed ID: 26340708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma.
    Feng H; Li B; Li Z; Wei Q; Ren L
    BMC Cancer; 2021 Apr; 21(1):401. PubMed ID: 33849479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma.
    Seo SI; Kim HS; Kim WJ; Shin WG; Kim DJ; Kim KH; Jang MK; Lee JH; Kim JS; Kim HY; Kim DJ; Lee MS; Park CK
    World J Gastroenterol; 2015 Apr; 21(13):3928-35. PubMed ID: 25852278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.
    Cui R; Wang B; Ding H; Shen H; Li Y; Chen X
    Chin Med J (Engl); 2002 Jan; 115(1):42-5. PubMed ID: 11930656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of serum prothrombin induced by vitamin K absence or antagonist-II in the early detection of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
    Yoon YJ; Han KH; Kim DY
    Scand J Gastroenterol; 2009; 44(7):861-6. PubMed ID: 19391065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Optimal cut-off value of PIVKA-II for diagnosis of hepatocellular carcinoma--using ROC curve].
    Kim MJ; Bae KW; Seo PJ; Jeong IK; Kim JH; Lee BH; Bang KT; Kim DW; Song IH
    Korean J Hepatol; 2006 Sep; 12(3):404-11. PubMed ID: 16998292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma.
    Ricco G; Cosma C; Bedogni G; Biasiolo A; Guarino M; Pontisso P; Morisco F; Oliveri F; Cavallone D; Bonino F; Plebani M; Brunetto MR
    Cancer Biomark; 2020; 29(2):189-196. PubMed ID: 32623383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection.
    Kim DY; Paik YH; Ahn SH; Youn YJ; Choi JW; Kim JK; Lee KS; Chon CY; Han KH
    Oncology; 2007; 72 Suppl 1():52-7. PubMed ID: 18087182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II.
    Caviglia GP; Abate ML; Gaia S; Petrini E; Bosco C; Olivero A; Rosso C; Ciancio A; Pellicano R; Saracco GM; Rizzetto M; Smedile A
    Panminerva Med; 2017 Dec; 59(4):283-289. PubMed ID: 28650134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma.
    Park SJ; Jang JY; Jeong SW; Cho YK; Lee SH; Kim SG; Cha SW; Kim YS; Cho YD; Kim HS; Kim BS; Park S; Bang HI
    Medicine (Baltimore); 2017 Mar; 96(11):e5811. PubMed ID: 28296720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of etiology of chronic liver disease on hepatocellular carcinoma biomarkers.
    Ricco G; Cavallone D; Cosma C; Caviglia GP; Oliveri F; Biasiolo A; Abate ML; Plebani M; Smedile A; Bonino F; Pontisso P; Brunetto MR
    Cancer Biomark; 2018 Feb; 21(3):603-612. PubMed ID: 29278878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of prothrombin induced by vitamin K absence, macrophage migration inhibitory factor and Golgi protein-73 versus alpha fetoprotein for hepatocellular carcinoma diagnosis and surveillance.
    Ismail MM; Morsi HK; Abdulateef NA; Noaman MK; Abou El-Ella GA
    Scand J Clin Lab Invest; 2017 May; 77(3):175-183. PubMed ID: 28276727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Could serotonin be a potential marker for hepatocellular carcinoma? A prospective single-center observational study.
    Abdel-Razik A; Elhelaly R; Elzehery R; El-Diasty A; Abed S; Elhammady D; Tawfik A
    Eur J Gastroenterol Hepatol; 2016 May; 28(5):599-605. PubMed ID: 26741637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic performance of tumor markers AFP and PIVKA-II in Chinese hepatocellular carcinoma patients.
    Huang S; Jiang F; Wang Y; Yu Y; Ren S; Wang X; Yin P; Lou J
    Tumour Biol; 2017 Jun; 39(6):1010428317705763. PubMed ID: 28621228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion.
    Poté N; Cauchy F; Albuquerque M; Voitot H; Belghiti J; Castera L; Puy H; Bedossa P; Paradis V
    J Hepatol; 2015 Apr; 62(4):848-54. PubMed ID: 25450201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels.
    Kang SH; Kim DY; Jeon SM; Ahn SH; Park JY; Kim SU; Kim JK; Lee KS; Chon CY; Han KH
    Eur J Gastroenterol Hepatol; 2012 Jul; 24(7):849-56. PubMed ID: 22495400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.